New shades of capitalism are emerging in China's tuckered out stock market as companies, at Beijing's behest, buy back their shares and pay record dividends to investors lying in wait for a so-far evasive rebound.

Currency traders looking for their next big idea could do worse than talk to Wong, who runs a news stand in Hong Kong’s Central District.

China announced plans on Thursday to channel hundreds of billions of yuan of investment from state-owned insurers into shares as part of the government's latest efforts to support a struggling stock market.

US President Donald Trump had threatened 60% tariffs on Chinese goods on his campaign trail.

Chinese electric vehicle battery giant CATL is pushing ahead with plans to list in Hong Kong, with banks reportedly vying for a deal expected to raise at least $5 billion.

The Company makes available through the Investor Relations section of its internet website at http://ir.yumchina.com its filings with the HKEX as soon as reasonably practicable after electronically filing such materials with the HKEX. These filings may also be obtained by visiting the HKEX's website at http://www.hkex.com.hk.

The Hong Kong stock market has finished higher in six straight sessions, rallying more than 1,230 points or 6 percent in that span.

The historic legislation for Basic Law Article 23, aimed at safeguarding national security and ensuring Hong Kong's stability and development, has topped a list of the ten most significant policies by the Hong Kong Special Administrative Region (HKSAR) government in 2024.

The Chinese government is trying to encourage people to spend more by ensuring that share prices will rise, ordering pensions and mutual funds to invest more in domestic stock markets

This is CNBC's live blog covering Asia-Pacific markets. Asia-Pacific markets rose Monday, ahead of Donald Trump's presidential inauguration as investors awaited greater clarity on the policies of the incoming U.S. administration. Hong Kong's Hang Seng ...

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to develop and commercialize ICP-B02 as a cancer drug outside of China. Prolium also has the right to develop ICP-B02 in non-cancer indications globally, according to a filling with the Hong Kong Stock Exchange (PDF).

To promote business collaboration and bilateral cooperation between the Hong Kong Special Administrative Region (HKSAR) and Indonesia, Mr Paul Chan, Financial Secretary of the HKSAR, visited Indonesia from January 8 – 10.